Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ziyi Lin, Lei Zhang, Xiaoyan Yang, Li Liu & Jianwei Xuan. (2020) Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China. Journal of Medical Economics 23:6, pages 659-666.
Read now
Read now
Oleg Borisenko, Vasily Lukyanov, Isabelle Debergh & Bruno Dillemans. (2018) Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. Journal of Medical Economics 21:4, pages 365-373.
Read now
Read now
C Knight, S Marbaix, L Annemans, J Prignot & K Bowrin. (2012) THE COST-EFFECTIVENESS OF AN EXTENDED COURSE (12+12 WEEKS) OF VARENICLINE PLUS BRIEF COUNSELLING COMPARED WITH OTHER REIMBURSED SMOKING CESSATION INTERVENTIONS IN BELGIUM, FROM A PUBLIC PAYER PERSPECTIVE. Acta Clinica Belgica 67:6, pages 416-422.
Read now
Read now
Manuela Helena Gschwend, Mark Aagren & William J Valentine. (2009) Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 12:2, pages 114-123.
Read now
Read now
Nowwar Mustafa & William Weintraub. (2007) Clopidogrel: a pharmacoeconomic review. Journal of Medical Economics 10:4, pages 553-571.
Read now
Read now
Mark D Schleinitz. (2006) The cost–effectiveness of clopidogrel: a review by indication. Expert Review of Pharmacoeconomics & Outcomes Research 6:2, pages 123-130.
Read now
Read now
Jon Karnon, Alan Brennan, Abdullah Pandor, Gerry Fowkes, Amanda Lee, David Gray, Catherine Coshall, Charles Nicholls & Ron Akehurst. (2005) Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Current Medical Research and Opinion 21:1, pages 101-112.
Read now
Read now
Wai Khoon Ho, Graeme J Hankey & John W Eikelboom. (2004) Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opinion on Pharmacotherapy 5:3, pages 493-503.
Read now
Read now
Articles from other publishers (18)
Te Li, Maobai Liu, He Ben, Zhenxing Xu, Han Zhong & Bin Wu. (2015) Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting. Clinical Drug Investigation 35:6, pages 365-374.
Crossref
Crossref
Thitima Kongnakorn, Tereza Lanitis, Lieven Annemans, Vincent Thijs, Marnix Goethals, Sophie Marbaix & Jean-Claude Wautrecht. (2014) Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. Clinical Drug Investigation 35:2, pages 109-119.
Crossref
Crossref
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts & Pierre Bartsch. (2015) Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Preventive Medicine Reports 2, pages 189-195.
Crossref
Crossref
Thitima Kongnakorn, Tereza Lanitis, Lievens Annemans, Vincent Thijs & Sophie Marbaix. (2014) Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium. Clinical Drug Investigation 34:10, pages 709-721.
Crossref
Crossref
Delphine De Smedt, Kornelia Kotseva, Dirk De Bacquer, David Wood, Guy De Backer, Jean Dallongeville, Lehto Seppo, Andrzej Pająk, Željko Reiner, Diego Vanuzzo, Borislav Georgiev, Nina Gotcheva & Lieven Annemans. (2012) Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. European Heart Journal 33:22, pages 2865-2872.
Crossref
Crossref
Koo WilsonRobert HettleSophie MarbaixSilvia Diaz CerezoMonica InesLaura SantoniLieven AnnemansJacques PrignotEsteban Lopez de Sa. (2011) An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. European Journal of Preventive Cardiology 19:5, pages 1173-1183.
Crossref
Crossref
Georgia Kourlaba, Vassilis Fragoulakis & Nikos Maniadakis. (2012) Clopidogrel versus Aspirin in Patients with Atherothrombosis. Applied Health Economics and Health Policy 10:5, pages 331-342.
Crossref
Crossref
J. Floris S. Logman, Bart M.S. Heeg, Johan Herlitz & Ben A. van Hout. (2010) Costs and Consequences of Clopidogrel versus Aspirin for Secondary Prevention of Ischaemic Events in (High-Risk) Atherosclerotic Patients in Sweden. Applied Health Economics and Health Policy 8:4, pages 251-265.
Crossref
Crossref
P. Berto, D. Inzitari, D. Scrutinio, C. Cimminiello, S. Lopatriello, G. Rudelli & G. Didoni. (2013) Clopidogrel idrogenosolfato versus aspirina nella riduzione degli eventi aterotrombotici nelle popolazioni a elevato rischio cardiovascolare: un’analisi italiana di costo-efficacia basata sul trial CAPRIEClopidogrel hydrogen sulfate versus aspirin: a cost-effectiveness Italian analysis from the CAPRIE trial. PharmacoEconomics Italian Research Articles 12:1, pages 33-50.
Crossref
Crossref
Lieven Annemans, Mark Lamotte, Peter Clarys & Eric Van den Abeele. (2016) Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases. European Journal of Cardiovascular Prevention & Rehabilitation 14:6, pages 815-824.
Crossref
Crossref
Jaime Fernández de Bobadilla, Carlos Calvo Gómez, Juan Antonio Gómez-Gerique, Pablo Lázaro, Ignacio Méndez & Mercedes García Vargas. (2013) Coste por año de vida ganado con atorvastatina 10 mg en pacientes hipertensos españoles en riesgo moderado: Evaluación económica del estudio ASCOT-LLA con costes españoles. PharmacoEconomics Spanish Research Articles 4:1, pages 11-24.
Crossref
Crossref
Carlos Calvo Gómez, Jaime Fernández de Bobadilla, Mercedes García Vargas, Peter Lindgren & Bengt Jönsson. (2013) Coste-efectividad de atorvastatina en hipertensos con riesgo moderado: evaluación económica del estudio ASCOT-LLA. PharmacoEconomics Spanish Research Articles 3:3, pages 123-135.
Crossref
Crossref
Mark Lamotte, Lieven Annemans, Pawel Kawalec & York Zoellner. (2006) A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction. PharmacoEconomics 24:8, pages 783-795.
Crossref
Crossref
Bernhard Schwarz & Sylvia Nanz. (2013) Die Kosteneffektivität von Clopidogrel bei Patienten mit Atherosklerose-assoziierten ErkrankungenCost Effectiveness of Clopidogrel in Patients with Atherosclerotic Diseases. PharmacoEconomics German Research Articles 3:1, pages 9-24.
Crossref
Crossref
Peter Lindgren, Martin Buxton, Thomas Kahan, Neil R. Poulter, Björn Dahlöf, Peter S. Sever, Hans Wedel & Beng Jönsson. (2017) Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA). European Journal of Cardiovascular Prevention & Rehabilitation 12:1, pages 29-36.
Crossref
Crossref
J. Jaime Caro, Khajak J. Ishak & Kristen Migliaccio-Walle. (2004) Estimating Survival for Cost-Effectiveness Analyses: A Case Study in Atherothrombosis. Value in Health 7:5, pages 627-635.
Crossref
Crossref
Isabelle Durand-Zaleski & Michel Bertrand. (2004) The Value of Clopidogrel versus Aspirin in Reducing Atherothrombotic Events. PharmacoEconomics 22:Supplement 4, pages 19-27.
Crossref
Crossref
Christopher P Cannon. (2004) Cost-Effectiveness of Clopidogrel. PharmacoEconomics 22:Supplement 4, pages 1-3.
Crossref
Crossref